Genome Editing among Bioethics and Regulatory Practices
Open Access
- 22 December 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 12 (1) , 13
Abstract
In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satisfactory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. Indeed, other factors (such as accessibility and acceptability) could make these techniques not accepted at the bioethical level, even in the presence of their 100% effectiveness.Keywords
This publication has 46 references indexed in Scilit:
- ZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringTrends in Biotechnology, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- Creation of a Bacterial Cell Controlled by a Chemically Synthesized GenomeScience, 2010
- CRISPR Provides Acquired Resistance Against Viruses in ProkaryotesScience, 2007
- Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal originMicrobiology, 2005
- Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic ElementsJournal of Molecular Evolution, 2005
- High frequency targeting of genes to specific sites in the mammalian genomeCell, 1986
- Replacement of chromosome segments with altered DNA sequences constructed in vitro.Proceedings of the National Academy of Sciences, 1979
- Will Society Be Prepared?Science, 1967